trexate — 25mg/mL soln for IV, IM, intra-arterial, or intrathecal admin after dilution See drug monograph and manufacturer’s full labeling. 1g pwd for IV, IM, intra-arterial, or intrathecal ...
Dexamethasone Intravitreal Implant Approved for ... antipsychotic drugs for the treatment of schizophrenia and bipolar mania in children and teens. News, June 11, 2009 FDA Approves Tacrolimus ...
China's Luye Pharma has claimed its first FDA approval ... bipolar disorder. Luye's injectables are based on a proprietary microsphere technology platform that controls the release of the active ...
It’s been more than three years since DBV Technologies’ peanuty allergy therapy was rejected for FDA approval, but the company thinks it now has a clear route to market with its patch product ...
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to ... including the treatment of ...
identified the FDA-approved immunosuppressant drug, sirolimus (also known as 'rapamycin'), as a therapeutic candidate for overcoming drug resistance in a form of human leukemia. These findings ...
Open and controlled studies indicate that divalproex is at least as effective as Li for treating acute mania in patients with bipolar disorder. Li and divalproex are the only FDA-approved drugs ...
Caplyta (lumateperone) is a brand-name oral capsule that’s prescribed for schizophrenia and bipolar depression ... Note: After the Food and Drug Administration (FDA) approves a drug, it tracks ...
Hosted on MSN11d
FDA Approves the First New Schizophrenia Drug in DecadesNo new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy ... whether it can ...
The drug, known as brexanalone, treats people who experience depression after giving birth, a condition known as post-partum depression. About two weeks ago, the FDA approved a treatment for ...
Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs ... with bipolar I or II disorder in adults. In April 2022, the FDA approved two new dosage ...
Stability milestone supports submission of US FDA new drug application by NRx ... for suicidal treatment-resistant bipolar depression and chronic pain. NRx Pharmaceuticals plans to file an NDA for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback